These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15682355)

  • 1. Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons.
    Fichtenbaum CJ
    HIV Clin Trials; 2004; 5(6):416-33. PubMed ID: 15682355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of lipid elevations associated with the treatment of patients with HIV infection.
    Piliero PJ
    MedGenMed; 2003 Jun; 5(2):1. PubMed ID: 14603100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.
    Aberg JA
    Top HIV Med; 2006; 14(4):134-9. PubMed ID: 17114827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population.
    Mehta N; Reilly M
    HIV Clin Trials; 2005; 6(1):5-24. PubMed ID: 15765307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for management and treatment of dyslipidemia in HIV/AIDS.
    Sax PE
    AIDS Care; 2006 Feb; 18(2):149-57. PubMed ID: 16338773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection.
    Barbaro G
    Clin Ter; 2008; 159(1):51-5. PubMed ID: 18399263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk among HIV-positive patients on antiretroviral therapy.
    Aberg JA
    J Int Assoc Physicians AIDS Care (Chic); 2003 Sep; 2 Suppl 2():S24-39. PubMed ID: 14569635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'.
    Acevedo M; Sprecher DL; Calabrese L; Pearce GL; Coyner DL; Halliburton SS; White RD; Sykora E; Kondos GT; Hoff JA
    Atherosclerosis; 2002 Aug; 163(2):349-54. PubMed ID: 12052482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular implications of HIV-induced dyslipidemia.
    Giannarelli C; Klein RS; Badimon JJ
    Atherosclerosis; 2011 Dec; 219(2):384-9. PubMed ID: 21722900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV and hyperlipidemia: current recommendations and treatment.
    Capili B; Anastasi JK
    Medsurg Nurs; 2006 Feb; 15(1):14-9, 35; quiz 20. PubMed ID: 16583530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease?
    Mooser V
    AIDS; 2003 Apr; 17 Suppl 1():S65-9. PubMed ID: 12870532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
    Grover SA; Coupal L; Gilmore N; Mukherjee J
    Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
    Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidemia related to antiretroviral therapy.
    Estrada V; Portilla J
    AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
    Dubé MP; Stein JH; Aberg JA; Fichtenbaum CJ; Gerber JG; Tashima KT; Henry WK; Currier JS; Sprecher D; Glesby MJ; ;
    Clin Infect Dis; 2003 Sep; 37(5):613-27. PubMed ID: 12942391
    [No Abstract]   [Full Text] [Related]  

  • 18. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk.
    Barbaro G; Barbarini G
    Chemotherapy; 2006; 52(4):161-5. PubMed ID: 16675900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
    Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
    J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between dyslipidemia and insulin resistance in HIV-infected persons treated with highly active antiretroviral therapy.
    Swanson B; Keithley JK; Zeller JM; Sha BE
    Nutrition; 2004; 20(11-12):1022-5. PubMed ID: 15561494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.